DexCom (DXCM)
(Delayed Data from NSDQ)
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.03 -0.21 (-0.29%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.03 -0.21 (-0.29%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Zacks News
DexCom (DXCM) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, DexCom (DXCM) stood at $122.17, denoting a -0.51% change from the preceding trading day.
3 Reasons Why Growth Investors Shouldn't Overlook DexCom (DXCM)
by Zacks Equity Research
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Penumbra (PEN) Stock Up 16.2% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), driven by growth in the vascular segments and upbeat guidance.
Thermo Fisher's (TMO) PPD Business Backs BARDA's Clinical Trial
by Zacks Equity Research
Thermo Fisher's (TMO) PPD clinical research business is selected by BARDA to support the Phase II platform clinical trial to treat ARDS.
Universal Health (UHS) Up 17% in 3 Months: More Growth Ahead?
by Zacks Equity Research
Universal Health (UHS) is well-poised for growth on the back of the resumption of elective procedures, acquisitions and solid operating cash flows.
Henry Schein (HSIC) Enters Orthopedic Market With New Buyout
by Zacks Equity Research
Henry Schein's (HSIC) recent deals will position it as a prominent producer and supplier in the orthopedic market's Foot and Ankle, Hand and Wrist extremity sectors.
Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.
Myriad Genetics' (MYGN) New Platform to Advance Cancer Care
by Zacks Equity Research
Myriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.
Bruker (BRKR) Installs First 1.2 GHz NMR at Ohio University
by Zacks Equity Research
Bruker (BRKR) 1.2 GHz AVANCE NMR spectrometer is cutting-edge equipment capable of performing high-resolution liquid and solid-state NMR studies.
Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes
by Zacks Equity Research
Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.
3 Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Venus Concept (VERO) Expands Global Reach With New Partnerships
by Zacks Equity Research
Venus Concept (VERO) expects its deals to fetch continued success in both the United Kingdom and India.
Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel
by Zacks Equity Research
Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.
DexCom's (DXCM) G7 CGM Connects With Tandem's Insulin Pump
by Zacks Equity Research
Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
Masimo's (MASI) Stork Baby Monitoring System Approved by FDA
by Zacks Equity Research
The latest FDA clearance of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.
Here's Why You Should Invest in Penumbra (PEN) Stock Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.
Align's (ALGN) Invisalign Palatal Expander System Gets FDA Nod
by Zacks Equity Research
Align's (ALGN) Invisalign Palatal Expander is the company's first direct 3D-printed orthodontic device. It offers a safe, pleasant and clinically effective alternative to traditional palatal expanders.
CVS Health (CVS) New Opportunities Drive Growth, Macro Woes Stay
by Zacks Equity Research
CVS Health's (CVS) restructuring plan poises it well, along with its strategic buyouts.
SenesTech (SNES) Likely to Expand Into China With New Deal
by Zacks Equity Research
This partnership provides SenesTech (SNES) with a gateway into one of the largest pest control markets globally, with the support and expertise of Fruit Tree.
Charles River's (CRL) Memphis Site Achieves Crucial Approval
by Zacks Equity Research
Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors remain optimistic about Tandem Diabetes (TNDM), backed by the impressive spree of product introductions.
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Abbott (ABT) Gains From Global Expansion Amid Macro Woes
by Zacks Equity Research
Abbott's (ABT) EPD business continues to witness low double-digit growth. It has successfully positioned itself as one of the best-positioned large healthcare companies in emerging markets.
Thermo Fisher (TMO) to Allocate IFA Testing Kits With New Pact
by Zacks Equity Research
Thermo Fisher (TMO) will continue to meet the evolving needs of laboratories and healthcare professionals by expanding its immunology product portfolio of EliA autoimmune diagnostics.